-
BOC/BOA Innovation Forum | Professor Xinan Sheng: An Overview of Advances in Kidney Cancer Treatment and the Pulse of Combination Therapy
Capturing Global Progress and Strategizing Kidney Cancer Diagnosis and Treatment Oncology Frontier: What unmet patient needs currently exist in kidney cancer treatment? Professor Xinan Sheng: Targeted-immunotherapy has become the main…
-
Professor Binghe Xu’s Team Publishes Research Results in Nature Communications
On June 27, 2024, Nature Communications published the results of a phase 1 clinical trial conducted by Professor Binghe Xu, an academician of the Chinese Academy of Engineering, and his joint team. The study focuses on a novel HER2 antibody-drug conjugate (ADC), FS-1502, which offers a potential new treatment option for HER2-positive breast cancer patients.
-
2024 CSCO YOUNG丨Professor Wenxing Qin: Small, Targeted Clinical Studies Can Also Improve Clinical Practice
The mid-year meeting of the Youth Expert Committee of the Chinese Society of Clinical Oncology (CSCO YOUNG) was held from June 28-30, 2024, in Shanghai. Young talents from across the country gathered to share experiences and discuss the future. Several experts shared their clinical and translational research experiences during the conference. Clinical research derived from…
-
BOC/BOA 2024 Preview | Professor Shukui Qin: Strengthening China’s Global Standing in Liver Cancer Diagnosis and Treatment with “Chinese Wisdom”
In recent years, there have been two significant changes in the field of liver cancer. On the one hand, with the development of treatment technologies, the prognosis of liver cancer patients has significantly improved, shedding its title as the “king of cancers.” On the other hand, China’s rapid advancements in liver cancer diagnosis and research…
-
ASCO Hot Review丨Professor Qiang Liu: The Prognostic Value of ctDNA in High-Risk Early-Stage Breast Cancer in the MonarchE Study
Circulating tumor DNA (ctDNA) is a novel liquid biopsy method that detects tumor-specific DNA mutations in the blood of breast cancer patients, helping to identify high-risk patients prone to recurrence and metastasis. Its prognostic value has been confirmed in multiple studies. At the 2024 ASCO conference, a study (Abstract LBA507) further analyzed the MonarchE study…
-
Case Sharing: The Mystery Behind Abdominal Distension
Hepatic sinusoidal obstruction syndrome (HSOS) is a hepatic vascular disease characterized by edema, necrosis, and detachment of the endothelial cells in the hepatic sinusoids, hepatic venules, and interlobular veins, leading to microthrombi formation, intrahepatic congestion, liver injury, and portal hypertension. Clinical manifestations include abdominal distension, liver pain, ascites, jaundice, and hepatomegaly. In cases of sudden…
-
ASCO in Five Minutes | Professor Chuanliang Cui: Advances in First-Line Treatment of Advanced Melanoma
With the continuous emergence of novel therapeutic agents, treatment strategies for advanced melanoma have evolved from traditional chemotherapy and radiotherapy to include immunotherapy, targeted therapy, chemotherapy, and their combinations. Global researchers are constantly exploring and optimizing treatment options for first-line therapy in advanced melanoma. At the 2024 American Society of Clinical Oncology (ASCO 2024) Annual…
-
Planning and Action: Leading Oncology Experts Discuss the Development and Future Prospects of ADCs in China
In recent years, with the advancement of innovative mechanisms and technologies, antibody-drug conjugates (ADCs) have become a research hotspot. ADC drugs have further promoted clinical development, clinical translation, and patient treatment outcomes. Recently, the high-level closed-door seminar “Planning and Action, Breaking Through the Billion-Dollar ADC Market,” hosted by the Oriental Clinical Oncology Research Center, China…
Connecting Medical Expertise through Media